J Clayton Allen1, Austin Kirschner2, Kristen R Scarpato3, Alicia K Morgans4. 1. Department of Medicine, Division of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, 691 Preston Research Building, Nashville, TN, 37232, USA. 2. Department of Radiation Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Preston Research Building Room B1003, Nashville, TN, 37232, USA. 3. Department of Urologic Surgery, Vanderbilt University, A-1302 Medical Center North, Nashville, TN, 37232, USA. 4. Department of Medicine, Division of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, 691 Preston Research Building, Nashville, TN, 37232, USA. alicia.morgans@vanderbilt.edu.
Abstract
PURPOSE OF REVIEW: We review current management strategies for patients with relapsed and refractory germ cell tumors (GCTs), defined as relapsed or persistent disease following at least one line of cisplatin-based chemotherapy. Additionally, we discuss future directions in the management of these patients. RECENT FINDINGS: Recent studies involving targeted therapies have been disappointing. Nevertheless, studies of the management of refractory germ cell cancer are ongoing, with a focus on optimal utilization of high-dose chemotherapy and autologous stem cell transplant, as well as the role of immune checkpoint inhibitors in refractory germ cell tumors. Studies aiming to identify those patients who may benefit from more intensive treatment up front to prevent the development of refractory disease are also in progress. Testicular germ cell tumors are among the most curable of all solid tumor malignancies, with cure being possible even in the refractory, metastatic setting. Treatment of refractory disease remains a challenging clinical scenario, but potentially practice changing studies are ongoing.
PURPOSE OF REVIEW: We review current management strategies for patients with relapsed and refractory germ cell tumors (GCTs), defined as relapsed or persistent disease following at least one line of cisplatin-based chemotherapy. Additionally, we discuss future directions in the management of these patients. RECENT FINDINGS: Recent studies involving targeted therapies have been disappointing. Nevertheless, studies of the management of refractory germ cell cancer are ongoing, with a focus on optimal utilization of high-dose chemotherapy and autologous stem cell transplant, as well as the role of immune checkpoint inhibitors in refractory germ cell tumors. Studies aiming to identify those patients who may benefit from more intensive treatment up front to prevent the development of refractory disease are also in progress. Testicular germ cell tumors are among the most curable of all solid tumor malignancies, with cure being possible even in the refractory, metastatic setting. Treatment of refractory disease remains a challenging clinical scenario, but potentially practice changing studies are ongoing.
Entities:
Keywords:
Cisplatin-refractory; Germ cell tumor; Platinum resistant; Refractory; Testicular cancer
Authors: C R Nichols; S D Williams; P J Loehrer; F A Greco; E D Crawford; J Weetlaufer; M E Miller; A Bartolucci; L Schacter; L H Einhorn Journal: J Clin Oncol Date: 1991-07 Impact factor: 44.544
Authors: Stuart Hinton; Paul J Catalano; Lawrence H Einhorn; Craig R Nichols; E David Crawford; Nicholas Vogelzang; Donald Trump; Patrick J Loehrer Journal: Cancer Date: 2003-04-15 Impact factor: 6.860
Authors: J Beyer; A Kramar; R Mandanas; W Linkesch; A Greinix; J P Droz; J L Pico; A Diehl; C Bokemeyer; H J Schmoll; C R Nichols; L H Einhorn; W Siegert Journal: J Clin Oncol Date: 1996-10 Impact factor: 44.544
Authors: C Kollmannsberger; O Rick; H-G Derigs; N Schleucher; P Schöffski; J Beyer; R Schoch; H G Sayer; A Gerl; M Kuczyk; C Spott; L Kanz; C Bokemeyer Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: C R Nichols; G Tricot; S D Williams; K van Besien; P J Loehrer; B J Roth; L Akard; R Hoffman; R Goulet; S N Wolff Journal: J Clin Oncol Date: 1989-07 Impact factor: 44.544
Authors: Michal Mego; Daniela Svetlovska; Vera Miskovska; Jana Obertova; Patrik Palacka; Jan Rajec; Zuzana Sycova-Mila; Michal Chovanec; Katarina Rejlekova; Peter Zuzák; Dalibor Ondrus; Stanislav Spanik; Maria Reckova; Jozef Mardiak Journal: Urol Oncol Date: 2015-11-21 Impact factor: 3.498
Authors: A Lorch; A Neubauer; M Hackenthal; A Dieing; J T Hartmann; O Rick; C Bokemeyer; J Beyer Journal: Ann Oncol Date: 2009-10-11 Impact factor: 32.976
Authors: Nirmish Singla; John T Lafin; Rashed A Ghandour; Samuel Kaffenberger; James F Amatruda; Aditya Bagrodia Journal: Curr Opin Urol Date: 2019-07 Impact factor: 2.309
Authors: Costantine Albany; Zeeshan Fazal; Ratnakar Singh; Emmanuel Bikorimana; Nabil Adra; Nasser H Hanna; Lawrence H Einhorn; Susan M Perkins; George E Sandusky; Brock C Christensen; Harold Keer; Fang Fang; Kenneth P Nephew; Michael J Spinella Journal: Cancer Med Date: 2020-11-01 Impact factor: 4.452
Authors: Dennis M Timmerman; Thomas F Eleveld; Ad J M Gillis; Carlijn C Friedrichs; Sanne Hillenius; Tessa L Remmers; Sruthi Sriram; Leendert H J Looijenga Journal: Int J Mol Sci Date: 2021-10-29 Impact factor: 5.923